Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...

2022-06-13 21:20 4307

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

Meness Aptieka earns the Best Place to Work certification in Latvia for 2022

RIGA, Latvia, June 13, 2022 /PRNewswire/ -- Mēness Aptieka, one of the largest pharmacy brands inLatvia, has earned the best place to work certification in Latvia for its first participation. According to the assessment results, 81% of employees said that they are proud to work for the organizati...

2022-06-13 16:27 2027

Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer

HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr.John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr.John ...

2022-06-13 08:00 3671

Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-06-13 08:00 4176

Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022

2022-06-13 08:00 4570

Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer

– Trodelvy is Everest's First Product to Receive Regulatory Approval in China – – Everest Plans to Launch Commercial Sales of Trodelvy in China in Q4 2022 – – Conference call will be held to discuss the approval– SHANGHAI, June 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", o...

2022-06-10 11:12 5526

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 4755

Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022

HANGZHOU, China and SAN FRANCISCO, June 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that two abstracts have been accepted for poster presen...

2022-06-09 08:00 3474

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval inthe United States and the European Union PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ -- Today, Medison Pharma ("Medison"), a g...

2022-06-08 23:54 3227

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...

2022-06-08 09:23 4291

First Patient Enrolled in SELUTION SLR IDE BTK Study

LEIPZIG, Germany, June 8, 2022 /PRNewswire/ -- The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just one week after receiving IDE approval.

2022-06-08 08:00 3596

First Patient Enrolled in SELUTION SLR IDE BTK Study

Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ot...

2022-06-08 08:00 4127

Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting

KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...

2022-06-07 14:00 2836

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathway. – This Phase I study will evaluate the safety, pharmacology and prelim...

2022-06-07 11:34 3735

Pharmactive Enters Strategic Partnership with Nutraconnect for APAC

Pharmactive targets Asia Pacific Market with new collaboration MADRID, June 7, 2022 /PRNewswire/ -- Pharmactive Biotech Products , S.L.U., announces a new strategic partnership withSingapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically ...

2022-06-07 09:00 3039

Pharmactive Enters Strategic Partnership with Nutraconnect for APAC

CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022

* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significant and clinically meaningful overall survival improvement in combination with chemotherapy for patients with treatment-naïve stage IV non-small cell lung cancer across both squamous and non-squamous ...

2022-06-07 08:02 4488

Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

* In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. * In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. * In 12 patients with brain metastasis and measurable...

2022-06-07 08:00 4103

Telix Showcasing Innovation in Theranostics at SNMMI

MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held inVancouver from June 11-14. Gallium-based pr...

2022-06-07 05:00 3126

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) FLORENCE, Ita...

2022-06-06 23:07 4317

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...

2022-06-06 21:00 3411

1 ... 148 149 150151152 153 154 ... 184